Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Liquidia Corp

NASDAQ: LQDA · Life Sciences · 16 alerts · CIK 1819576

Share price
$56.37Close, Nov 16
Market cap
$5.08B
Shares outstanding
90.11MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Liquidia Corp filings on SEC EDGAR ↗

7:01 AM ET 8-K
Financial Results

Liquidia Financial Results

Liquidia Corporation reported Q3 2026 financial results, highlighted by $222.7 million in YUTREPIA net product sales, a 31% increase over the prior quarter. The company recorded a net loss of $236.3 million, which was primarily driven by a $389.7 million litigation settlement charge to resolve all outstanding disputes with United Therapeutics. Liquidia ended the quarter with $396.1 million in cash and cash equivalents.

Term
Q3 2026

“Five quarters after launch, YUTREPIA has rapidly established a preferred product profile because physicians value the control and flexibility it gives them over each patient’s therapy. That affinity and broad adoption have proven durable and our business continues to grow in parallel. With the litigation now fully resolved, and YUTREPIA’S commercial availability secure, we can fully focus on cementing the value of YUTREPIA through Phase 4 studies in PAH that will position it as the best-in-class inhaled therapy and first-in-choice prostacyclin.”

Dr. Roger Jeffs, Liquidia’s Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.